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Abstract: The role of the parallel expression of the KAI1 protein and metalloproteinases (MMP-2 and MMP-9) 
in respect to the status of steroid receptors in endometrial cancer is still incompletely understood. The aim 
of this study was to evaluate the expression of and correlation between KAI1 on one hand and MMP-2 and 
MMP-9 on the other hand in terms of the status of the estrogen (ER) and progesterone receptors (PR) in 
100 patients with endometrial cancer. The expressions of KAI1, MMP-2, MMP-9, ER and PR were assessed 
immunohistochemically on paraffin-embedded tissues. No correlations were found between these biomarkers 
and the clinical and pathological parameters of the endometrial cancer. However, in KAI1-positive cases, the 
expression was limited to a small area of tumor tissue in FIGO stages III–IV. A tendency towards the high 
expression of MMP-9 and MMP-2 was observed in the advanced stages of endometrial cancer (FIGO IIIA–IV). 
Positive correlations between the presence of KAI1 and PR and between the presence of MMP-9 and PR were 
found in endometrial cancer. A positive correlation was also observed between KAI1 and MMP-2 expression, 
and a borderline one between KAI1 and MMP-9 expression in endometrial cancer. KAI1+/PR+ and KAI1+/ER– 
immunophenotypes were observed more frequently in FIGO low stages and with well-differentiated tumor 
grade. However, the KAI1–/ER+ and KAI1–/PR+ immunophenotypes were mainly observed in advanced stages 
of endometrial cancer. KAI1+/MMP-2+ and KAI1+/MMP-9+ immunophenotypes were observed in FIGO I 
stage and with well-differentiated tumors. KAI1–/MMP-2+ and KAI1–/MMP-9+ phenotypes were more often 
observed in FIGO stage II. Our study showed that KAI1 protein, as well as steroid receptors, might modulate 
MMP-2 and MMP-9 expression in endometrial cancer. Our study revealed that the overlapping expression of the 
biomarkers investigated here suggests that cooperation between these molecules exists, even at the early stages 
of endometrial cancer growth, and may determine the speed of tumor cell dissemination and might characterize 
the biological behavior of endometrial cancer. (Folia Histochemica et Cytobiologica 2014, Vol. 52, No. 3, 187–194)
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Introduction
Endometrial cancer is the most common malignancy 
of the female genital tract in developed countries 
[1–3]. The mortality rate in Europe is about 9000 per 
year. According to Cancer Incidence in Five Continents 
and the International Agency for Research on Can-
cer, the global morbidity rate is 6.5% and the global 
mortality rate is about 1.6% [1–4]. 
The risk factor is based on the range of glandular 
and nonglandular epithelial components [5]. In endo-
metrial cancer, even in cases diagnosed at stages I and 
II of the FIGO classification, a cancer recurrence or 
metastatic spread can appear [6]. To assess the risk of 
recurrence in patients with endometrial cancer, many 
biological factors, such as tyrosine kinase receptors, 
steroid receptors, and proteins associated with me-
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tastasis, have been analyzed [7]. For a solid tumor, 
the neoplastic cell population must spread from the 
primary tumor to the surrounding tissues, in order to 
find an area amenable to growth. This process may 
occur at an early stage of tumor development [8]. Park 
et al. [9] revealed that, during metastases, different 
signaling pathways in tumor cells may be activated. An 
experimental study revealed that this expansion can 
be clonal and limited to a more biological aggressive 
subpopulation of tumor cells [9]. The first stage of 
tumor invasion involves degradation of the basement 
membrane, caused selectively by metalloproteinases 
(MMPs) [10]. MMPs play important roles in invasion 
and metastasis by regulating the signaling pathways 
that control cell growth and invasion [10]. Of all the 
metalloproteinases, the type-IV collagenase group of 
MMP-2 and MMP-9 has been linked to endometrial 
cancer progression and invasion [6]. Expression of 
different factors facilitates a subclone of a tumor cell 
growing to micrometastasis, allowing tumor cell out-
growth at a new, distant site [10]. Upexpression and 
downexpression of several genes that play different 
roles in a cell — including metastasis suppressor genes 
— has been described as occurring in the metastatic 
process [11]. KAI1 is a member of the tetraspan 
transmembrane superfamily (TM4SF) of type-III 
membrane proteins. It was originally identified as 
a metastasis suppressor in prostate cancer [12]. KA1 is 
an important tumor metastasis suppressor gene whose 
inactivation plays a crucial role in the tumor meta-
stasis process [11, 12]. KAI1 expression is frequently 
downregulated in many human cancers, including 
endometrial cancer [13]. Experimental data has shown 
that the KAI1 protein may mediate growth-suppres-
sive signals, which lead to the induction of the p21 
protein in melanoma cells [11]. Additionally, KAI1 
interacts with different proteins, such as epidermal 
growth factor receptor (EGFR) and Src (intracellular 
tyrosine kinase) and plays a role in a functional signa-
ling network that influences the metastatic potential 
of cancer [9].
The role of MMP and KAI1 expression in tumor 
metastasis is still controversial [12, 14, 15]. Moreover, 
some reports have revealed their important roles in 
endometrial cancer invasion [15]. Similarly, there is 
data that MMP expression is regulated by different 
factors, such as p53, p48, ETS, and ERK1/2 [8, 10]. 
To our knowledge, there are no studies that analyzed 
the relationship between the expression of the KAI1 
protein, MMP-2, and MMP-9 in endometrial cancer 
in respect to steroid receptor status, with the aim of 
showing whether these proteins are jointly involved 
in the invasive growth of endometrial cancer. The 
present study evaluates the expression of and the 
correlation between KAI1 and MMP-2 and MMP-9 
in respect to the status of estrogen receptors (ER) and 
progesterone receptors (PR) in endometrial cancer. 
Material and methods
Patients. From 1995 to 2008, tissue samples were collected 
from 100 patients diagnosed with endometrial cancer un-
dergoing surgery in the First Clinic of Gynecology, Wroclaw 
Medical University in Poland. None of the women had 
received radiotherapy or chemotherapy prior to surgery. 
The tumor tissues were histologically verified to confirm 
the diagnosis, histological type, and grade, according to 
the World Health Organization criteria [16] and the FIGO 
classification (2009). 
Immunohistochemistry. Immunohistochemical staining for 
the proteins under investigation was performed on paraf-
fin-embedded tissue using the Universal DakoCytomation 
LSAB+ Kit peroxidase procedure (LSAB+ Kit:HRP, Dako, 
Copenhagen, Denmark). The tissue samples were treated 
with primary monoclonal mouse antibodies against steroid 
receptors ER (clone 6F11, Novocastra, Newcastle, UK) and 
PR (clone 1A6, Novocastra), against the metalloproteinases 
MMP-2 (clone 17B11, Novocastra) and MMP-9 (clone 203, 
Novocastra), and against the metastatic suppressor protein 
KAI1 (clone G-2, Santa Cruz Biotechnology, Santa Cruz, 
CA, USA). Dilutions of 1:50, 1:50, 1:80, 1:40, and 1:50 of 
the stock primary antibodies were used for ER, PR, MMP-2, 
MMP-9, and KAI1 detection, respectively.
Five-micrometer-thick sections from one selected block 
from each lesion were deparaffinized and boiled for 3 × 5 mi-
nutes for each antibody in a citrate buffer (pH 6.0) at 700 W 
in a microwave oven. After the microwave treatment, the 
tissue sections were cooled slowly for 20 minutes. Endoge-
nous peroxidase reactivity was blocked with 3% H2O2 and 
nonspecific tissue reactions with 10% bovine serum albumin. 
Tissue specimens were incubated with primary monoclonal 
antibodies. Following washing with 0.1 M Tris-buffer of 
pH = 7.4 (TBS), the tissue specimens were incubated with 
secondary biotinylated rabbit antibody (Dako), anti-mouse 
IgG and with streptavidin conjugated to horseradish pe-
roxidase (Dako), both for 15 minutes at room temperature. 
After washing with TBS, the antigen–antibody reaction was 
visualized with DAB (3,3-diaminobenzidine) (Dako) as 
a chromogen (8 min, room temperature). Sections were 
counterstained with hematoxylin and mounted. The incuba-
tion buffer (TBS), without a primary antibody, was used as 
a negative control. The internal positive controls were per-
formed according to manufacturer’s procedure to confirm 
the specificity of the immunostaining. The following positive 
controls were used: lobular breast carcinoma for estrogen 
and progesterone receptors, sarcoma tissue for MMP-2, 
macrophages for MMP-9, and tonsil for KAI1 protein. 
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Interpretation of immunostaining results. The preparations 
were evaluated under a BH-2 Olympus light microscope 
(Olympus, Tokyo, Japan). The localization, distribution, 
and intensity of the immunostaining were assessed in the 
tissue sections. The semiquantitative evaluation of the IHC 
staining was performed without knowledge of the clinical 
data, and a consensus was reached on controversial cases. 
To evaluate the PR and ER, we applied the criteria used in 
endometrial adenocarcinoma immunostaining [2].
The nuclear immunostaining for estrogen and progeste-
rone receptors was recorded as the percentage of positively 
stained cells with positive samples, defined as those showing 
more than 10% stained cells. For MMP-2 and MMP-9, 
cytoplasmic immunostaining (and for KAI1 membrane im-
munostaining) was considered as positive when more than 
10% of the tumor tissue showed immunopositivity [14, 15]. 
The intensity of staining was scored 0 for negative, + for 
weak, ++ for moderate, and +++ for strong. 
Statistical analysis. The correlations between the steroid 
receptors (ER, PR) and MMP-2, MMP-9, and KAI1 protein 
expression with the clinical and pathological parameters 
of the endometrial carcinomas were statistically evaluated 
using the chi-square test. Associations between the biomar-
kers were analyzed using the Spearman rank correlation. 
Differences were considered significant at p ≤ 0.05. 
Results 
All the biomarkers investigated showed a heteroge-
neous pattern of immunoreactivity. Depending of 
the markers assessed, positive immunostaining was 
observed in 10% to 90% of tumor lesions. Positive nuc-
lear expression of ER and PR was found in 46.0% and 
51.0% of endometrial cancer cases, respectively. Strong 
expression of both steroid receptors was found in the 
glandular structure of the tissue (Figure 1A, B). Diffuse 
Figure 1. Immunoexpression of the studied proteins in the endometrial cancer. The nuclear expression of (A) estrogen 
(ER) and (B) progesterone (PR) receptors. The cytoplasmic localization of MMP-2 (C) and MMP-9 (D). The membrane 
localization of KAI1 (E). Immunostaining was performed using the avidin–biotin staining (ABC method) as described in 
Methods. Total magnification × 400
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cytoplasmic localization of MMP-2 and MMP-9 was 
observed in 41.0% and 59.0% of endometrial cancers, 
respectively. The expression of MMP-2 and MMP-9 
dominated in the center of the tissue and was reduced 
at the edge of the carcinoma structure (Figure 1C, D). 
In half of all cases, MMP-2 and MMP-9 expression 
was found in stromal tissue surrounding the tumor 
structures; however, the immunostaining was stronger 
in the tumor cells than in the stromal cells. Membrane 
KAI1 protein expression was found in 60.0% of cases. 
The cells expressing KAI1 protein formed nests, and 
were distributed in tubular structures of neoplastically 
altered tissue (Figure 1E). Heterogeneous staining for 
KAI1 protein was observed not only between different 
endometrial cancer cases, but also in individual cases. 
KAI1 expression was not found in stromal tissue.
No correlations were seen between the studied bio-
markers and the clinical or pathological parameters 
of endometrial cancer (see Table 1). Interestingly, in 
KAI1-positive cases, the expression was dependent on 
the stage of the disease and was limited to a small area 
of tumor tissue in FIGO stages III–IV. A tendency 
towards the high expression of MMP-9 and MMP-2 
was found in the advanced stages of endometrial 
cancer (FIGO IIIA–IV). The differences were not 
statistically significant (p > 0.05). The expression of 
all the biomarkers was analyzed by tumor grade G1 
versus grade G2/G3. Independent of tumor grade, the 
expression of all proteins was comparable (Table 1).
In further analysis, we estimated the association 
between steroid receptor, KAI1, and metalloproteina-
se (MMP-2, MMP-9) expression in the whole group 
of endometrial cancer, as well as for the FIGO stage 
and tumor grade, to determine the overlapping effect 
of the investigated biomarkers in endometrial cancer 
progression.
Positive correlations between KAI1 protein and 
PR, and between MMP-9 and PR presence, were 
found in endometrial cancer (p = 0.01, r = +0.24; 
p = 0.02, r = +0.22 respectively) (Table 2). A positive 
correlation was observed between KAI1 and MMP-2 
expression (p = 0.04; r = +0.19) and a borderline 
correlation was seen between KAI1 and MMP-9 
(p = 0.07; r = +0.18) in endometrial cancers (Table 3).
Taking into account the level of MMP-2, MMP-9, 
and KAI1 concomitant expression in endometrial 
cancer samples in relation to ER and PR expression, 
it is worth underlining that the KAI1+/PR+ and 
KAI+/ER– immunophenotypes were observed more 
frequently in low FIGO stage and well-differentiated 
tumor grades. In contrast, KAI1–/ER+ and KAI1–/PR+ 
immunophenotypes were mainly observed in the 
advanced stages of endometrial cancer. Endome-
trial cancers showing KAI1+/MMP-2+ or MMP-9+ 
immunophenotypes were observed in FIGO stage I 
and well-differentiated tumors. KAI1–/MMP-2+ and 
MMP-9+ cases, however, were observed in FIGO 
stage II (Table 4).
Discussion
The key step in endometrial cancer invasion involves 
the degradation of extracellular matrix components 
and the migration of cancer cells into other organs [10]. 
Invasion by tumor cells is characterized by a down-
-regulation or upregulation of metastasis suppressor 
genes [12]. KAI1 is a basic protein that determines 
the motility and invasiveness of cells [14]. So far, the 
biology and the interaction of KAI1 with other pro-
teins related to metastasis are unknown. In line with 
previous result [13, 15, 17, 18], we found in this study 
that the expression of steroid receptors, metallopro-
Table 1. Expression of KAI1, MMP-2, MMP-9, ER, and PR in endometrial cancers in relation to clinical and pathological 
parameters
Clinical and pathological  
parameters
Number of immunoreactive cases (percentage)
Number  
of patients





FIGO IA 47 28 (59.5) 18 (38.2) 21 (44.6) 19 (40) 26 (55.3) NS
FIGO IB–II 46 27 (58.6) 19 (41.3) 26 (56.2) 18 (39.1) 28 (60.8) NS
FIGO IIIA–IVB 7 5 (71.4) 4 (57.1) 4 (57.1) 4 (57.1) 5 (71.4) NS
TOTAL 100 60 (60) 41 (41) 51 (51) 41 (41) 59 (59) NS
G1 67 41 (61.1) 25 (37.3) 33 (49.2) 28 (41.7) 39 (58.2) NS
G2 (n = 24) + G3 (n = 9) 33 19 (57.5) 16 (48.4) 18 (54.3) 13 (39.3) 20 (60.6) NS
TOTAL 100 60 (60) 41 (41) 51 (51) 41 (41) 59 (59) NS
G1, G2, G3 — grade of tumor differentiation; NS — not significant
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teinases, and KAI1 protein was observed in similar 
percentages of endometrial cancers.
In contrast to the current study, there is in the 
literature data that shows the association between 
MMP-2 and MMP-9 expression and the FIGO stage 
of endometrial cancer [19]. However, there is also data 
that, like our results, reveals no correlation between 
the examined MMPs and clinical and pathological 
parameters [6, 7, 15]. It is worth mentioning that, in 
our study, the expression of MMP-2 and MMP-9 was 
observed mainly in cases with advanced FIGO stage, 
and that MMP-9 immunopositivity was found in 
a greater area of tissue than in the case of cancers 
with less advanced FIGO stages.
The increased expression of MMP-2 and MMP-9 
in advanced stages of endometrial cancer indicates 
that both enzymes are involved in tumor progression 
and may play an important role in the dissemination 
of tumor cells acting via basement membrane degra-
dation [10, 15]. On the other hand, recent data shows 
that MMPs play mainly an indirect role in the cell 
signaling pathway through the activity of biomolecules 
that target specific receptors that are responsible for 
cell growth and migration. Such a mechanism can be 
considered during endometrial cancer growth as 
a hormone-dependent tumor [19]. 
In agreement with earlier data on KAI1 expression 
in gastric, breast, head and neck cancers [14, 20, 21], 
we observed a loss of KAI1 protein expression in 
almost half of primary endometrial cancers. KAI1- 
-negative tumors were found frequently in poorly dif-
ferentiated cases, similarly to the situation previously 
described with gastric cancer [20]. In our study, KAI1 
downregulation was not significantly associated with 
an advanced clinical stage of disease. This may be due 
to the limited number of cases in FIGO III and IV. 
Nevertheless, we observed the trend toward KAI1 
downregulation in the form of increased stages of 
endometrial tumor, consistent with the postulated role 
of KAI1 as a suppressor protein of tumor aggressive 
growth [11]. 
Increasing attention has been paid to the in-
teraction between different factors involved in 
metastatic processes in hormone-sensitive tumors 
[22–24]. To our knowledge, this is the first study 
which has analyzed the association between stero-
id receptors, KAI1 protein, MMP-2, and MMP-9 
— as well as between KAI1, MMP-2, and MMP-9 




(number of positive or negative cases)
Estrogen receptor (ER) 
(number of positive or negative cases)
PR+ PR– ER+ ER–









MMP-2– 30 29 25 34




MMP-9– 18 23 17 24
R — rank correlation; p — p-value; NS — not significant
Table 3. Correlations between examined biomarkers in endometrial cancers
Immunoreactivity (number of positive or negative cases)
Proteins studied KAI1+ KAI1–
MMP-2+ 30 11 p = 0.04
R = +0.19MMP-2– 30 29
MMP-9+ 39 20 p = 0.07
R = +0.18MMP-9– 21 20
R — rank correlation; p — p-value
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— in endometrial cancer. Earlier studies revealed 
that KAI1 protein may cooperate with MMPs, and 
displays a different role in its functions in ER-ne-
gative and ER-positive breast cancers [14, 22, 23]. 
Christgen et al. [22, 23] found that in ER-positive 
breast cancers the KAI1 protein was downregulated. 
However, more aggressive breast cancers commonly 
express KAI1 protein. In our study, KAI1 expression 
was independent of ER status in endometrial cancer 
but was dependent on PR expression. The absence of 
correlation between KAI1 protein and ER expression 
in the present study contradicts the data obtained by 
Christgen et al., who reported the downregulation of 
KAI1 expression by estrogen [22]. There is no data 
describing any association between KAI1 and PR 
expression in human tumors. In our study, PR-positive 
endometrial cancers overexpressed the KAI1 protein. 
These results indicate that the mechanism which acti-
Table 4. Distribution of different immunophenotypes in relation to the clinicopathological parameters of endometrial 
cancer
Clinical and pathological parameters Immunophenotypes of endometrial cancer 
(number of cases, all cases n = 100)
KAI1+/ER+ KAI1+/ER– KAI1+/PR+ KAI1+/PR–
FIGO IA 10 18 17 11
FIGO IB–II 9 17 14 13
G1 12 29 23 20
G2 7 7 7 4
G3 4 1 5 1
KAI1–/ER+ KAI1–/ER– KAI1–/PR+ KAI1–/PR–
FIGO IA 8 11 4 15
FIGO IB–II 10 9 12 7
G1 12 15 10 16
G2 6 5 5 5
G3 2 2 1 3
KAI1+/MMP-9+ KAI1+/MMP-9– KAI1+/MMP-2+ KAI1+/MMP-2–
FIGO IA 19 9 15 13
FIGO IB–II 17 10 11 16
G1 28 29 23 20
G2 8 7 7 4
G3 4 1 5 1
KAI1–/MMP-9+ KAI1–/MMP-9– KAI1–/MMP-2+ KAI1–/MMP-2–
FIGO IA 7 12 4 15
FIGO IB–II 11 9 7 12
G1 12 14 8 18
G2 4 5 2 8
G3 4 0 1 3
G1, G2, G3 — grades of tumor differentiation
vates the biological function of KAI1 in endometrial 
cancers is different than in the case of breast can - 
cer [23]. The positive correlation between KAI1 
protein expression and PR in endometrial cancer 
reveals the cooperation between those proteins, and 
the synergic inhibiting effect of both proteins could 
be considered in these cases. These suggestions might 
be supported by the presence of parallel KAI1/PR 
expression in early stages of endometrial cancer. On 
the other hand, the data indirectly suggests that PR 
expression, as with other receptors, may enhance 
KAI1 expression, thus suppressing the mobility of the 
tumor cells and their migration from the tumor mass 
to surrounding tissues [21]. The differences between 
our study and other studies might be explained by the 
different source of biological material. In contrast to 
our study on tumor tissue, most results describing the 
metastatic ability of tumor cells have been performed 
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on cell lines or animal models [8, 25, 26]. The results 
from in vitro studies are not comparable with the data 
from tumor tissue, which is not as homogenic as a cell 
line [25, 26]. The results of the present study show 
that MMP-9 expression was significantly higher in 
patients with a high level of PR, and that there was 
a significant positive correlation between MMP-9 and 
PR, but not between MMP-9 and ER expression, as 
well as between MMP-2, ER, and PR in endometrial 
cancer. These results differ from those reported for 
breast tumor tissue sections [27, 28], which found that 
ER-negative breast cancer had higher expression of 
MMP-9, while PR-positive breast cancer had high 
levels of MMP-2 expression. 
There is a lack of published reports regarding 
possible associations between the status of steroid re-
ceptors and the expression of MMP-2 and MMP-9 in 
endometrial cancer. However, some results imply that 
MMP-2 and MMP-9 expression could be hormonally 
regulated in endometrial cancer. This suggestion might 
be supported by data which shows that the expression 
of MMP-2 depends on PR isoforms. PR-B has been 
found to decrease MMP-2 expression and PR-A to 
increase MMP-2 expression in human deciduas [29]. 
In our study, we might consider such regulation of 
MMP-2 and MMP-9 by isoforms of ERa, b, PR-A, 
and PR-B playing different biological functions in 
tumor cells [19]. Our data, showing a positive relation 
between KAI1 and MMP-2 expression in endometrial 
cancers, are partly consistent with recently published 
results which have shown a relationship between the 
expression of KAI1, MMP-2, and MMP-9 in bladder 
cancer cell lines [30]. The authors of that study showed 
that poorly invasive KAI1-positive cell lines express 
high levels of MMP-2 mRNA and (pro-MMP-2) 
protein, whereas cell lines that are KAI1-negative 
and possess an invasive phenotype show no detecta-
ble MMP-2 mRNA expression [30]. The same study 
indicated that some cell lines showed pro-MMP-2 
protein but no gelatinolytic activity, and its authors 
suggested that the levels of KAI1 might be directly 
related to MMP-2 mRNA and MMP-2 activity [30]. 
In our present study, we analyzed the expression of 
the KAI1 and MMP-2 proteins, and not the mRNA 
level of the MMP-2 gene. Our results, however, sho-
wed the association between both proteins existing 
in endometrial cancer in early FIGO stage, which 
could suggest that the KAI1 protein might reduce the 
gelatinolytic activity of MMP-2 [11, 30]. Similarly to 
the results of recent reports, no association was found 
between KAI1 and MMP-9 expression in endometrial 
cancer [30]. Based on analyses comparing immuno-
phenotypes with the clinicopathological parameters 
of endometrial cancers, we can suggest that, of the 
studied proteins, KAI1 expression is the most impor-
tant factor in the progression of the tumor in the early 
stages of endometrial cancer growth.
In conclusion, our results show that KAI1 protein, 
as well as steroid receptors, might modulate the level 
of MMP-2 and MMP-9 expression in endometrial 
cancer. The positive and negative cooperation be-
tween these biomarkers exists in the early stages of 
endometrial cancer growth, and might determine the 
speed of the dissemination of tumor cells and reflect 
the biological behavior of the tumor.
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